Compare JFU & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | LSTA |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 28.9M |
| IPO Year | 2018 | 2000 |
| Metric | JFU | LSTA |
|---|---|---|
| Price | $2.68 | $1.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 8.1K | ★ 537.0K |
| Earning Date | 12-09-2022 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.98 | $0.99 |
| 52 Week High | $9.48 | $5.07 |
| Indicator | JFU | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 44.49 |
| Support Level | $2.06 | $1.23 |
| Resistance Level | $2.94 | $2.08 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 52.17 | 36.08 |
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.